Shinemage Group Appoints Maye Musk and Song Seung Heon as Brand Ambassadors for Oganacell
Ambassador - Maye Musk
Ambassador - Song Seong Heon
HONG KONG SAR - Media OutReach Newswire - 16 June 2025 - On May 20, 2025, Premium derma-cosmetic brand Oganacell named Maye Musk as Cleansing/Mask Ambassador and Song Seung Heon as Brand Ambassador at its global launch in Hangzhou. The event showcased Oganacell's fusion of technology and skin aesthetics.fronts the "Dust It Off" campaign, stating: "Oganacell helps me reconnect with myself through cleansing rituals and gives me 20 minutes of relaxation everyday."noted: "Skin recalibration isn't fighting time, but letting skin find its rhythm."Dr. Oh Gana champions "skin recalibration" through personalized regimens. Oganacell is building a worldwide skin database to redefine treatment standards. He says, "The differentiation of Oganacell is that our product research is based on our uinque client group. We have a variety of high-end clients from the royal families, the Chaebol families, Politicians, Governors and artists worldwide.R&D Head Jung Bok-kyung launched the DERX™ Oxygen Cleansing Series and V-mode Contour Recalibration Series – clinically proven formulas replicating in-office procedures.Global Impact: The event united 1,000+ top beauty professionals, influencers, buyers, and consumers from 10+ countries, reaching over 100 million globally, marking a definitive global beauty moment.Highlights included:A "Future Skin Recalibration Space" with holographic consultations and interactive diagnostics.Oganacell dermatologist group live consultation.AI photo experiences.Hangzhou not only marks the launch of the Oganacell brand and also the global journey of Shinemage Group.Hashtag: #Oganacell
The issuer is solely responsible for the content of this announcement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malay Mail
8 hours ago
- Malay Mail
Shanghai Healthcare M&A Fund Takes Strategic Stake in MicroPort Scientific Corporation
HONG KONG SAR - Media OutReach Newswire - 25 July 2025 – MicroPort Scientific Corporation (Stock Code: "MicroPort") announced that Shanghai Healthcare M&A Fund ("SHMAF"), a fund managed by SIIC Capital, a subsidiary of SIIC Group, has entered into a share purchase agreement to acquire 135,335,204 shares in MicroPort held by Otsuka Medical Devices Co., Ltd. Through this transaction, SHMAF will become a strategic shareholder in MicroPort, underscoring its role as a state-backed, professionally operated platform that is creating value and empowering, stabilizing, developing, and reshaping leading biopharmaceutical companies in a homegrown Chinese innovator that has grown into a global leader in high-end medical devices, MicroPort serves as an anchor company for the industry. Its stable development is critical to both China's and the global high-end medical device supply chain. This investment reflects SHMAF's capital-driven approach to providing crucial support to domestic anchor companies, ensuring their stability and support growth of their core assets. SHMAF will support MicroPort's growth momentum and high-quality sustainable development with its expansive transaction brings in a significant strategic shareholder for MicroPort. Leveraging its state-backed resources and industrial expertise, SHMAF will support MicroPort's development needs, core business expansion, and potential strategic mergers and acquisitions to create synergies that bolster the company's ongoing innovation and scale-up its has successfully incubated and nurtured multiple listed companies and specialized, highly influential small companies, in the process establishing a unique MicroPort ecosystem. SHMAF will leverage its capital and operational integration expertise to support MicroPort in refining its development strategy, optimizing resource allocation, and unlocking synergistic value—while fully respecting market dynamics and corporate autonomy—to further strengthen its ecosystem and competitive product portfolio spans across ten major verticals, including cardiovascular intervention, rhythm management, orthopaedics, neurovascular intervention, and surgical robotics, making it a core player in the high-end medical device industrial chain. SHMAF's support will not only drive MicroPort's growth, it will also accelerate its consolidation of upstream and downstream companies in Shanghai, attract highly-skilled talent, and facilitate breakthroughs in critical technologies and core components—ultimately enhancing the global competitiveness of China's high-end medical device transaction marks another significant step in SHMAF's commitment to serving biopharmaceutical anchor companies. Upholding its value investment principles, SHMAF will collaborate with MicroPort's shareholders and management team to leverage the strategic support and industrial synergies its state-backed platform offers. Together, they will reinforce MicroPort's position as China's innovation engine in high-end medical devices and contribute to the advancement of the biopharmaceutical #SIICCapital #MicroPort #SHMAF The issuer is solely responsible for the content of this announcement. About MicroPort Scientific Corporation Founded in 1998 and headquartered in Shanghai's Zhangjiang, MicroPort Scientific Corporation is a leading domestic innovative high-end medical device group. It began by breaking the import monopoly in the cardiovascular stent field, and after 26 years of innovative development, its business has expanded to areas including rhythm management, orthopaedics, cardiovascular intervention, aortic and peripheral vascular intervention, neurovascular intervention, heart valves, surgical robots, and surgical medical devices. By the end of 2024, MicroPort operated in over 20,000 hospitals across 100 countries and regions worldwide, providing more than 600 solutions for patients covering over 200 diseases. MicroPort has incubated 6 A-share and Hong Kong-listed companies, owns 9 specialized and sophisticated SMEs, 4 technology giant enterprises, and 16 national high-tech enterprises, making it an outstanding representative of Shanghai's technological innovation and industrial transformation. About SIIC Capital As the active fund management platform under SIIC Group, since its establishment, SIIC Capital has been based in Shanghai, connected with Hong Kong, and oriented towards the world, actively exploring investment opportunities in strategic emerging industries such as biomedicine and green environmental protection. Through a multi-currency, full-stage fund matrix layout, it deeply serves national strategies and the construction of biomedicine highlands.
The Sun
14 hours ago
- The Sun
Amazon closes Shanghai AI lab amid US-China tech tensions
SHANGHAI: US tech giant Amazon has closed its artificial intelligence research lab in Shanghai, according to a source familiar with the matter. The lab, part of Amazon Web Services (AWS), was disbanded as AI becomes a key battleground in US-China tech competition. A WeChat post by Wang Minjie, a scientist at the lab, stated the closure was due to 'strategic adjustment between China and the United States.' The post circulated widely on Chinese social media this week. AWS recently announced job cuts, with reports suggesting hundreds of positions were affected. Amazon did not directly confirm the Shanghai lab's shutdown when contacted but acknowledged broader restructuring. 'We've made the difficult business decision to eliminate some roles across particular teams in AWS,' said spokesman Brad Glasser. 'These decisions are necessary as we continue to invest, hire, and optimize resources.' The AWS China webpage for the lab, previously accessible, was taken down this week. Archived records show the lab was launched in 2018 to foster research collaboration. Other US tech firms, including Microsoft and IBM, have also reduced research operations in China as geopolitical tensions persist. - AFP
New Straits Times
16 hours ago
- New Straits Times
TikTok will go dark in US without Chinese approval of sale deal, US commerce secretary says
BENGALURU: US Commerce Secretary Howard Lutnick said on Thursday that TikTok will have to stop operating in the United States if China does not approve a deal for the sale of the Chinese-owned short video app that is used by some 170 million Americans. Lutnick, speaking on CNBC, also said the United States must control the algorithm that makes the social media platform work. Last month, President Donald Trump extended by 90 days to Sept 17, 2025 a deadline for China-based ByteDance to divest the US assets of TikTok. Trump's action took place despite a 2024 law that mandated a sale or shutdown by Jan 19, 2025 if there had not been significant progress. "China can have a little piece or ByteDance, the current owner, can keep a little piece. But basically, Americans will have control. Americans will own the technology, and Americans will control the algorithm," Lutnick said. "If that deal gets approved, by the Chinese, then that deal will happen. If they don't approve it, then TikTok is going to go dark, and those decisions are coming very soon." TikTok did not immediately comment. A deal had been in the works this spring that would spin off TikTok's US operations into a new US-based firm, majority-owned and operated by US investors. This stalled after China indicated it would not approve it following Trump's announcements of steep tariffs on Chinese goods. Trump has three times granted reprieves from federal enforcement of the law that mandated the sale or shutdown of TikTok that was supposed to take effect in Jan 2025. Attorney General Pam Bondi sent letters to Apple, Google and other companies that provide services or host the TikTok app that were made public this month. The letters said the Justice Department was irrevocably relinquishing any claims against the companies for potential violations of the law, citing Trump's determination that an abrupt shutdown would interfere with his overseeing national security and foreign affairs. Some Democratic lawmakers argue Trump has no legal authority to extend the deadline and suggest the deal under consideration would not meet legal requirements.
